Key issues concerning fungistatic versus fungicidal drugs (Q41377981)

30 September 2017

1 reference

title

Key issues concerning fungistatic versus fungicidal drugs (English)

1 reference

30 September 2017

Graybill JR

1

1 reference

30 September 2017

Burgess DS

series ordinal

2

1 reference

30 September 2017

Hardin TC

series ordinal

3

1 reference

30 September 2017

1 January 1997

1 reference

European Journal of Clinical Microbiology & Infectious Diseases

30 September 2017

1 reference

30 September 2017

16

1 reference

30 September 2017

1

1 reference

30 September 2017

42-50

1 reference

https://scigraph.springernature.com/pub.10.1007/bf01575120

30 September 2017

0 references

cites work

In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01575120

In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01575120

Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis

21 January 2018

1 reference

12 December 2020

Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature

1 reference

12 December 2020

A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group

1 reference

12 December 2020

Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.

1 reference

12 December 2020

Beneficial Effect of Recombinant Human Granulocyte Colony-Stimulating Factor on Fungicidal Activity of Polymorphonuclear Leukocytes from Patients with AIDS

1 reference

12 December 2020

A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).

1 reference

12 December 2020

Oral azole drugs as systemic antifungal therapy

1 reference

12 December 2020

Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS.

1 reference

12 December 2020

1 reference

12 December 2020

Amphotericin B in the treatment of coccidioidomycosis.

1 reference

12 December 2020

Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome

1 reference

12 December 2020

Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome

1 reference

12 December 2020

Amphotericin B induces tumor necrosis factor production by murine macrophages

1 reference

12 December 2020

In-vitro activity of SCH39304 in comparison with amphotericin B and fluconazole

1 reference

12 December 2020

Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome.

1 reference

12 December 2020

Resistance of Candida species to fluconazole

1 reference

12 December 2020

Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis

1 reference

12 December 2020

Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils

1 reference

12 December 2020

Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

1 reference

12 December 2020

Protective effect of human granulocyte colony stimulating factor (hG-CSF) on Candida, infections in normal and immunosuppressed mice

1 reference

12 December 2020

Infectious complications in adults with bone marrow transplantation and T-cell depletion of donor marrow. Increased susceptibility to fungal infections

1 reference

12 December 2020

Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo

1 reference

12 December 2020

Interaction of Chemotherapy and Immune Defenses in Experimental Murine Cryptococcosis

1 reference

12 December 2020

High-dose fluconazole for treatment of cryptococcal disease in patients with human immunodeficiency virus infection. The California Collaborative Treatment Group

1 reference

12 December 2020

Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections

1 reference

12 December 2020

Identification of patients with acute AIDS-associated cryptococcal meningitis who can be effectively treated with fluconazole: the role of antifungal susceptibility testing

1 reference

12 December 2020

Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

1 reference

12 December 2020

Antifungal susceptibility tests

1 reference

12 December 2020

Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole

1 reference

12 December 2020

Enhancement of macrophage superoxide anion production by amphotericin B

1 reference

12 December 2020

In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans

1 reference

12 December 2020

Correlation between in vitro and in vivo activity of antifungal agents against Candida species

1 reference

12 December 2020

Amphotericin B-induced oxidative damage and killing of Candida albicans

1 reference

12 December 2020

Annulment of amphotericin B inhibition of Coccidioides immitis endospores. Effects on growth, respiration and morphogenesis

1 reference

12 December 2020

A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group

1 reference

12 December 2020

Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis

1 reference

12 December 2020

Use of amphotericin B with azole antifungal drugs: what are we doing?

1 reference

12 December 2020

Intravascular catheter exchange and duration of candidemia. NIAID Mycoses Study Group and the Candidemia Study Group

1 reference

12 December 2020

In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184

1 reference

12 December 2020

Concomitant amphotericin B therapy, granulocyte transfusions, and GM-CSF administration for disseminated infection with Fusarium in a granulocytopenic patient

1 reference

12 December 2020

Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: reliability of relatively high doses administered over a relatively short period.

1 reference

12 December 2020

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

1 reference

12 December 2020

Is it ever safe to stop azole therapy for Coccidioides immitis meningitis?

1 reference

12 December 2020

Treatment of murine histoplasmosis with UK 49,858 (fluconazole)

1 reference

12 December 2020

Pharmacologic modulation of interleukin-1 expression by amphotericin B-stimulated human mononuclear cells

1 reference

12 December 2020

Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis

1 reference

12 December 2020

Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B.

1 reference

12 December 2020

Combined therapy with fluconazole and flucytosine in murine cryptococcal meningitis

1 reference

12 December 2020

Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group

1 reference

12 December 2020

Discrepancies between MIC and MLC values of amphotericin B against isolates of Aspergillus species.

1 reference

12 December 2020

A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis

1 reference

12 December 2020

Inactivation of amphotericin B by reducing agents: Influences on growth inhibition ofCandida albicansand lysis of erythrocytes

1 reference

12 December 2020

A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group

1 reference

12 December 2020

Cryptococcosis in the acquired immunodeficiency syndrome

1 reference

12 December 2020

Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer

1 reference

12 December 2020

Susceptibility of Candida albicans and other yeasts to fluconazole: relation between in vitro and in vivo studies

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01575120

1 reference

Dimensions Publication ID

30 September 2017

0 references

1 reference